Board of Directors - Dianthus Therapeutics

Alison Lawton is an executive leader with more than 35 years of experience in biopharma. She served as President and Chief Executive Officer of Kaleido Biosciences, Inc. from August 2018 to June 2020, and served as President and Chief Operating Officer from December 2017 to August 2018. Prior to joining Kaleido, Ms. Lawton served as Chief Operating Officer at Aura Biosciences, Inc., an oncology therapeutics company, from January 2015 until December 2017, and, prior to joining Aura, served as a consultant to Aura from March 2014 to December 2014. From January 2013 to January 2014, Ms. Lawton served as Chief Operating Officer at OvaScience Inc., a life sciences company. From 2014 to 2017, Ms. Lawton served as a biotech consultant for various companies, including as Chief Operating Officer consultant at X4 Pharmaceuticals. Prior to that, Ms. Lawton spent more than 20 years in various positions of increasing responsibility including Senior Vice President and General Manager of Biosurgery and prior, Senior Vice President of Global Regulatory Affairs & Market Access at Genzyme Corporation, and subsequently at Sanofi S.A. following the acquisition of Genzyme by Sanofi in 2011. Additionally, Ms. Lawton previously served two terms as the industry representative on the U.S. Food & Drug Administration’s Cell & Gene Therapy Advisory Committee and as Chairman of the Board of the Regulatory Affairs Professional Society. Ms. Lawton currently serves on the Board of Directors of ProQR Therapeutics N.V., is the Chair of the board of directors of the private company TRIMTECH Therapeutics and is a director of the private company BlueRock Therapeutics LP. Ms. Lawton holds a B.Sc. in pharmacology from Kings College, University of London. Ms. Lawton previously served on the boards of directors of Spyre Therapeutics Inc. (Nasdaq: SYRE), SwanBio Therapeutics, AgBiome LLC and Kaleido (Nasdaq: KLDO), Verastem, Inc. (Nasdaq: VSTM), CoLucid Pharmaceuticals, Inc., (Nasdaq: CLCD) a formerly public biotechnology company, Cubist Pharmaceuticals, Inc.,(Nasdaq: CBST) a formerly public biopharmaceutical company and X4 Pharmaceuticals Inc.

Anne McGeorge has almost 40 years of experience providing strategic guidance and operational oversight to health care organizations. Ms. McGeorge currently serves as the Chairman of the Board of Directors, as well as a member of the Compensation Committee, at The Oncology Institute, Inc. She also serves on the Board of Directors, as well as the Audit Committee Chair of two private companies, CitiusTech, a health care technology company, and Nimbus Therapeutics, LLC, a biotech company. She is also on the board of CLEAR Insurance, a Cayman based captive insurance company, the National Marrow Donor Program (aka Be The Match), a 501(c)(3) organization, the William and Mary Raymond Mason School of Business Foundation, and is on the advisory board at FCA Healthcare Innovations, a venture capital company. Additionally, Ms. McGeorge previously served on the Board of Directors of SOC Telemed, Inc. from October 2020 until it was acquired by Patient Square Capital, Inc. Ms. McGeorge is also on the adjunct faculty at the University of North Carolina at Chapel Hill. Prior to her retirement in July 2017, Ms. McGeorge worked at Grant Thornton LLP where she routinely advised clients on audit, tax, and financial matters relating to the healthcare industry. During her time at Grant Thornton LLP, Ms. McGeorge was Managing Partner of Grant Thornton LLP’s Health Care Industry Practice from January 2006 to July 2017, as well as Global Managing Partner for Grant Thornton International’s Health Care Industry Practice from August 2015 to July 2017. Ms. McGeorge was formerly a partner at Deloitte LLP from 2002 to 2005 and at Arthur Andersen LLP from 1997 to 2002. Ms. McGeorge received a B.B.A., Business, Accounting from the College of William and Mary, and an M.S., Accounting/Taxation from the University of Virginia. LinkedIn Profile

Dr. Violin co-founded Dianthus in July 2019 and has served on the Board of Directors since. Dr. Violin has served as a Venture Partner at Fairmount Funds Management LLC (“Fairmount”), a healthcare investment firm, since June 2023, and as President, Interim CEO, and member of the Board of Directors of Crescent BioPharma, Inc. since October 2024. Prior to joining Fairmount, he was the President and Chief Executive Officer of Viridian Therapeutics, Inc., which he also co-founded, and is an accomplished scientist and experienced leader in drug discovery and development, and in scientific platform development. He previously served as founding Chief Executive Officer of Quellis Biosciences, which was acquired by Astria Therapeutics, Inc. in 2018, and served on the Astria Therapeutics board of directors from January 2021 until it’s acquisition by BioCryst Pharmaceuticals in January 2026. Prior to that, Dr. Violin co-founded and helped lead Trevena Inc. from discovery research through clinical development and NDA submission, including multiple rounds of venture and public financing. Dr. Violin holds a Ph.D. from the Department of Pharmacology at the University of California, San Diego, an M.B.A. with a concentration in Health Sector Management from the Fuqua School of Business, and a B.S. in Chemical Pharmacology from Duke University.

Ms. Soteropoulos has more than 35 years of biopharma industry experience in strategic and operational leadership areas including drug development, global commercialization, manufacturing, new company formation and company building. In addition to a strong focus on rare disease, her career spans a broad range of therapeutic areas including cardiovascular and metabolism, neurology, infectious disease, renal, and transplant and oncology. She currently serves as Chairman of the Board of Ensoma, where she played an instrumental role in launching the company from its venture seed stage. Ms. Soteropoulos also serves on the Board of Directors for Rallybio, Kyowa Kirin North America and Metri Bio, and is an advisor to Chiesi Rare Disease. Previously, she served as founding CEO and member of the Board of Directors at Akcea Therapeutics, where she led the company through its IPO and commercial launch of two rare disease medicines and also served as a board member of uniQure for 11 years. Prior to Akcea, she was Senior Vice President and General Manager of Cardiometabolic and Rare Disease Businesses and Strategic Alliances at Moderna, Inc. Before Moderna, Ms. Soteropoulos spent more than 20 years at Genzyme Corporation where she held positions of increasing responsibility including Vice President and General Manager, Cardiovascular, Rare Diseases. Ms. Soteropoulos earned an executive management certificate from the University of Virginia – Darden Graduate School of Business Administration and both Bachelor and Master of Science degrees in Chemical and Biochemical Engineering from Tufts University.

Dr. Romano has served as the EVP, Chief Research and Development Officer of Silence Therapeutics, Inc. since June 2024, and prior to that at Silence Therapeutics he was the Head of Research and Development from April 2023 to June 2024, and a Non-Executive Director from July 2019 to April 2023. Dr. Romano is a pharmaceutical executive and board-certified psychiatrist and pharmaceutical executive with over 28 years of drug development experience across a wide range of therapeutic and disease areas. Dr. Romano served as Executive Vice President and Chief Scientific Officer at Mallinckrodt Pharmaceuticals, where he had responsibility for research and development, regulatory, safety sciences and medical affairs from May 2015 to December 2022. Prior to joining Mallinckrodt, Dr. Romano spent 16 years at Pfizer, Inc. where he held a series of senior research and development and medical roles, culminating in his final position as SVP, Head, Global Medicines Development, Global Innovative Pharmaceuticals Business. He has recently served as Chairman of the Board of the National Pharmaceutical Council, a non-profit health policy research organization, and is a past president of the International Society for CNS Clinical Trials and Methodology, an independent organization focused on enhancing therapeutic development of central nervous system therapeutics. Dr. Romano received his M.D. from the University of Missouri-Columbia School of Medicine and graduated from Washington University in St. Louis with a bachelor’s degree in biology and English literature.

Mr. Kango is an experienced executive with more than 26 years of experience in the pharmaceutical and biotechnology sector. Mr. Kango is the Co-Founder of Oorja Bio and has served as its President and CEO since September 2023. His vast, results-oriented experience ranges from serving as both public and private company board member to being a C-suite executive of multi-billion dollar public companies. He previously served on the boards of Adante, Inc., MEI Pharma and Infinity Pharmaceuticals. Mr. Kango was the President and Chief Executive Officer of Tmunity Therapeutics, a clinical stage research and development CAR-T therapy company that was acquired by Gilead Sciences in February 2023 for an undisclosed amount. From 2018-2021, he served as the EVP, Chief Commercial Officer of Acceleron Pharma, which was acquired by Merck & Co. for over $11.5 billion. Mr. Kango has been responsible for over 5 blockbuster products and launches, including Reblozyl, Nexavar, Kyprolis, Peg-Intron, and Remicade. He earned a B.S. in Microbiology and an M.B.A. from McNeese State University.

Dr. Read is a serial entrepreneur with more than 30 years of biopharmaceutical experience.

Dr. Read most recently served as CEO and founder of Mariana Oncology until its acquisition by Novartis and was Chief Scientific Officer at Ra Pharma (NASDAQ: RARX) until its acquisition by UCB Pharma. Prior to this, he held R&D leadership roles at GlaxoSmithKline, AstraZeneca and Roche/Genentech and worked on the clinical development of some of the most well-known drugs in the immunology area, including Rituxan® and Actemra®. Dr. Read is a Fellow of the Royal Society of Medicine (UK) and Chairman of the Board of Ethyreal Bio. He previously served on the Board of Triana Biomedicines and Oxstem Ltd (UK). He obtained his Ph.D. from University of Hertfordshire, studied Physiology at the University of Manchester in the UK, and has authored over 50 articles in peer reviewed journals.

Mr. Garcia joined Dianthus in November of 2021 with a successful 27-year track record of building and transforming organizations in operational, strategic, commercial, and business developmental leadership roles with various small, mid-cap and large biopharmaceutical companies, including Eli Lilly, Pfizer, Aspreva (acquired by Vifor Pharma), Aptalis (acquired by Forest Labs), and Synergy. Prior to joining Dianthus, he served as Senior Vice President, Corporate and Business Development at Zealand Pharma. In this role, he sourced, negotiated, and executed various strategic transactions, including an exclusive discovery and development collaboration with Alexion Pharmaceuticals focused on peptide therapies for complement-mediated diseases. After beginning his career in large multinational biopharmaceutical companies, Marino shifted course to work with biotechnology start-ups, starting with Aspreva, a company collaborating with Roche to develop CellCept (myocophenolate mofetil) for a range of autoimmune diseases, including Lupus Nephritis, Myasthenia Gravis, and Pemphigus Vulgaris. Marino received his M.B.A from the Ivey Business School at Western University in London, Ontario and his Bachelor of Commerce from Concordia University in Montreal, Quebec.